4qim › Citations

Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs.

Wang C, Wu H, Evron T, Vardy E, Han GW, Huang XP, Hufeisen SJ, Mangano TJ, Urban DJ, Katritch V, Cherezov V, Caron MG, Roth BL, Stevens RC
Nat Commun 5 4355 (2014)
Related entries: 4n4w, 4qin

Cited: 139 times
EuropePMC logo PMID: 25008467

Abstract

The Smoothened receptor (SMO) mediates signal transduction in the hedgehog pathway, which is implicated in normal development and carcinogenesis. SMO antagonists can suppress the growth of some tumours; however, mutations at SMO have been found to abolish their antitumour effects, a phenomenon known as chemoresistance. Here we report three crystal structures of human SMO bound to the antagonists SANT1 and Anta XV, and the agonist, SAG1.5, at 2.6-2.8 Å resolution. The long and narrow cavity in the transmembrane domain of SMO harbours multiple ligand binding sites, where SANT1 binds at a deeper site as compared with other ligands. Distinct interactions at D473(6.54f) elucidated the structural basis for the differential effects of chemoresistance mutations on SMO antagonists. The agonist SAG1.5 induces a conformational rearrangement of the binding pocket residues, which could contribute to SMO activation. Collectively, these studies reveal the structural basis for the modulation of SMO by small molecules.

Reviews - 4qim mentioned but not cited (4)

  1. G protein-coupled receptors: structure- and function-based drug discovery. Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y, Yuliantie E, Xie L, Tao H, Cheng J, Liu Q, Zhao S, Shui W, Jiang Y, Wang MW. Signal Transduct Target Ther 6 7 (2021)
  2. A comprehensive review of the lipid cubic phase or in meso method for crystallizing membrane and soluble proteins and complexes. Caffrey M. Acta Crystallogr F Struct Biol Commun 71 3-18 (2015)
  3. Structural Studies of G Protein-Coupled Receptors. Zhang D, Zhao Q, Wu B. Mol Cells 38 836-842 (2015)
  4. Smoothened goes molecular: new pieces in the hedgehog signaling puzzle. McCabe JM, Leahy DJ. J Biol Chem 290 3500-3507 (2015)

Articles - 4qim mentioned but not cited (16)



Reviews citing this publication (51)

  1. Hedgehog Signaling: From Basic Biology to Cancer Therapy. Wu F, Zhang Y, Sun B, McMahon AP, Wang Y. Cell Chem Biol 24 252-280 (2017)
  2. Structural insights into G-protein-coupled receptor allostery. Thal DM, Glukhova A, Sexton PM, Christopoulos A. Nature 559 45-53 (2018)
  3. Wnt signaling in triple-negative breast cancer. Pohl SG, Brook N, Agostino M, Arfuso F, Kumar AP, Dharmarajan A. Oncogenesis 6 e310 (2017)
  4. Biochemical mechanisms of vertebrate hedgehog signaling. Kong JH, Siebold C, Rohatgi R. Development 146 dev166892 (2019)
  5. Novel Allosteric Modulators of G Protein-coupled Receptors. Gentry PR, Sexton PM, Christopoulos A. J Biol Chem 290 19478-19488 (2015)
  6. Regulation of the oncoprotein Smoothened by small molecules. Sharpe HJ, Wang W, Hannoush RN, de Sauvage FJ. Nat Chem Biol 11 246-255 (2015)
  7. Cholesterol access in cellular membranes controls Hedgehog signaling. Radhakrishnan A, Rohatgi R, Siebold C. Nat Chem Biol 16 1303-1313 (2020)
  8. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Wu Q, Qian W, Sun X, Jiang S. J Hematol Oncol 15 143 (2022)
  9. Strategies to target the Hedgehog signaling pathway for cancer therapy. Xin M, Ji X, De La Cruz LK, Thareja S, Wang B. Med Res Rev 38 870-913 (2018)
  10. An Insight into GPCR and G-Proteins as Cancer Drivers. Chaudhary PK, Kim S. Cells 10 3288 (2021)
  11. Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. Roth BL, Kroeze WK. J Biol Chem 290 19471-19477 (2015)
  12. Smoothened Regulation: A Tale of Two Signals. Arensdorf AM, Marada S, Ogden SK. Trends Pharmacol Sci 37 62-72 (2016)
  13. Hedgehog signaling pathway: a novel model and molecular mechanisms of signal transduction. Gorojankina T. Cell Mol Life Sci 73 1317-1332 (2016)
  14. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer. Carpenter RL, Ray H. Drug Saf 42 263-279 (2019)
  15. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Jain S, Song R, Xie J. Onco Targets Ther 10 1645-1653 (2017)
  16. Sending and Receiving Hedgehog Signals. Petrov K, Wierbowski BM, Salic A. Annu Rev Cell Dev Biol 33 145-168 (2017)
  17. I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs. Chen JK. Nat Prod Rep 33 595-601 (2016)
  18. Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance. Nguyen NM, Cho J. Int J Mol Sci 23 1733 (2022)
  19. Large-scale production and protein engineering of G protein-coupled receptors for structural studies. Milić D, Veprintsev DB. Front Pharmacol 6 66 (2015)
  20. Cellular and molecular mechanisms of Hedgehog signalling. Zhang Y, Beachy PA. Nat Rev Mol Cell Biol 24 668-687 (2023)
  21. Multi-functionality of proteins involved in GPCR and G protein signaling: making sense of structure-function continuum with intrinsic disorder-based proteoforms. Fonin AV, Darling AL, Kuznetsova IM, Turoverov KK, Uversky VN. Cell Mol Life Sci 76 4461-4492 (2019)
  22. Multiple ligand binding sites regulate the Hedgehog signal transducer Smoothened in vertebrates. Byrne EF, Luchetti G, Rohatgi R, Siebold C. Curr Opin Cell Biol 51 81-88 (2018)
  23. Structures of vertebrate Patched and Smoothened reveal intimate links between cholesterol and Hedgehog signalling. Kowatsch C, Woolley RE, Kinnebrew M, Rohatgi R, Siebold C. Curr Opin Struct Biol 57 204-214 (2019)
  24. Successful Strategies to Determine High-Resolution Structures of GPCRs. Xiang J, Chun E, Liu C, Jing L, Al-Sahouri Z, Zhu L, Liu W. Trends Pharmacol Sci 37 1055-1069 (2016)
  25. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors. Pietrobono S, Stecca B. Cells 7 E272 (2018)
  26. Integrating structural and mutagenesis data to elucidate GPCR ligand binding. Munk C, Harpsøe K, Hauser AS, Isberg V, Gloriam DE. Curr Opin Pharmacol 30 51-58 (2016)
  27. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. Gutzmer R, Solomon JA. Target Oncol 14 253-267 (2019)
  28. Serial Femtosecond Crystallography of G Protein-Coupled Receptors. Stauch B, Cherezov V. Annu Rev Biophys 47 377-397 (2018)
  29. Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Lee HM, Kim Y. Schizophr Res Treatment 2016 6378137 (2016)
  30. FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review. Sochacka-Ćwikła A, Mączyński M, Regiec A. Cancers (Basel) 14 87 (2021)
  31. Frizzleds and WNT/β-catenin signaling--The black box of ligand-receptor selectivity, complex stoichiometry and activation kinetics. Schulte G. Eur J Pharmacol 763 191-195 (2015)
  32. A Molecular Pharmacologist's Guide to G Protein-Coupled Receptor Crystallography. Piscitelli CL, Kean J, de Graaf C, Deupi X. Mol Pharmacol 88 536-551 (2015)
  33. Design of Hedgehog pathway inhibitors for cancer treatment. Bariwal J, Kumar V, Dong Y, Mahato RI. Med Res Rev 39 1137-1204 (2019)
  34. Hedgehog pathway and smoothened inhibitors in cancer therapies. Chahal KK, Parle M, Abagyan R. Anticancer Drugs 29 387-401 (2018)
  35. Ciliary Genes in Renal Cystic Diseases. Adamiok-Ostrowska A, Piekiełko-Witkowska A. Cells 9 E907 (2020)
  36. Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Jin G, Sivaraman A, Lee K. Arch Pharm Res 40 1390-1393 (2017)
  37. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y, Zhou C. Signal Transduct Target Ther 8 315 (2023)
  38. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Doan HQ, Chen L, Nawas Z, Lee HH, Silapunt S, Migden M. Oncotarget 12 2089-2100 (2021)
  39. Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma. Cosio T, Di Prete M, Campione E. Biomedicines 8 E156 (2020)
  40. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Sochacka-Ćwikła A, Mączyński M, Regiec A. Molecules 27 2259 (2022)
  41. Identifying G protein-coupled receptor dimers from crystal packings. Stenkamp RE. Acta Crystallogr D Struct Biol 74 655-670 (2018)
  42. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Zhang H, Sun Z, Liu Z, Song C. Future Med Chem 10 2855-2875 (2018)
  43. An outlook on using serial femtosecond crystallography in drug discovery. Mishin A, Gusach A, Luginina A, Marin E, Borshchevskiy V, Cherezov V. Expert Opin Drug Discov 14 933-945 (2019)
  44. Patidegib in Dermatology: A Current Review. Cosio T, Di Prete M, Di Raimondo C, Garofalo V, Lozzi F, Lanna C, Dika E, Orlandi A, Rapanotti MC, Bianchi L, Campione E. Int J Mol Sci 22 10725 (2021)
  45. Function and structure of bradykinin receptor 2 for drug discovery. Shen JK, Zhang HT. Acta Pharmacol Sin 44 489-498 (2023)
  46. Mapping oncogenic protein interactions for precision medicine. Sharifi Tabar M, Francis H, Yeo D, Bailey CG, Rasko JEJ. Int J Cancer 151 7-19 (2022)
  47. The role of experimental and computational structural approaches in 7TM drug discovery. Topiol S, Sabio M. Expert Opin Drug Discov 10 1071-1084 (2015)
  48. Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics. Maschinot CA, Pace JR, Hadden MK. Curr Med Chem 22 4033-4057 (2015)
  49. The structural biology of canonical Wnt signalling. Agostino M, Pohl SÖ. Biochem Soc Trans 48 1765-1780 (2020)
  50. Towards Precision Oncology: The Role of Smoothened and Its Variants in Cancer. Nicheperovich A, Townsend-Nicholson A. J Pers Med 12 1648 (2022)
  51. Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings. Al Jaf AIA, Peria S, Fabiano T, Ragnini-Wilson A. Cells 13 1326 (2024)

Articles citing this publication (68)



Quick links